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In the July 2009 issue of the journal Clinical Infectious
Diseases, the Infectious Diseases Society of America
(IDSA) published an update of their ‘Clinical Practice
Guidelines for the Diagnosis and Management of Intravas-
cular Catheter-Related Infection’ [1]. The largest part of
the IDSA text relates to non-dialysis catheters, and it is
not always clear how far these general recommendations
can be extrapolated to the haemodialysis condition. A spe-
cific section of the IDSA guidelines is, however, devoted
to haemodialysis catheters.
In the present position statement by European Renal
Best Practice (ERBP), we intend to focus on the items in
these guidelines which are relevant for nephrologists and
to amend them to haemodialysis conditions and/or for
the European situation with regards to tunnelled catheters.
ERBP is the new guidance body of the European Renal
Association-European Dialysis and Transplantation Asso-
ciation (ERA-EDTA), replacing European Best Practice
Guidelines (EBPG) since 2008.
We will discuss only those IDSA guidelines worth
reflection or amendment. The corresponding IDSA
guidelines will be mentioned between parentheses ().
Guidelines which we did not consider for discussion,
although they still might be relevant, are summarized in
Table 1.
The present text has been issued in accordance with the
new philosophy of ERBP to offer guidance by means of
position statements commenting on documents issued by
other guideline bodies or on recent relevant studies, next
to ad hoc recommendations when not enough evidence
is available [2,3]. Real guidelines are to be issued only
in case of sufficient evidence. ERBP recently published
two position statements along these principles [4,5].
Of note, earlier EBPG recommendations have been is-
sued on vascular access and infectious disease in haemo-
dialysis patients [6,7]. The current document further
elaborates and updates these documents.
The IDSA guidelines are well written with a clear dis-
tinction between several subheadings, covering a general
and a specific part. The same guidelines are frequently re-
peated, and the same items are also often covered both in
the general and specific guidelines, albeit that the recom-
mendations are not always exactly the same. The grading
system is not the same as the one currently propagated by
Grading of Recommendations, Assessment, Development
and Evaluation (GRADE) and applied by ERBP and Kid-
ney Disease: Improving Global Outcomes (KDIGO)
[3,8,9.]: it is a nine-tiered system with three levels of ev-
idence and three levels of strength vs two levels of evi-
dence and four levels of strength for the three bodies
mentioned above. Although the majority of IDSA guide-
lines are based on only one or two non-randomized trials
often generated by one single research group, most of
them are graded as level A.II, with only seven of 123 re-
commendations (5.7%) having the highest level (A.I). Al-
though A.II gives the impression of being based on robust
evidence, ‘dramatic results even from uncontrolled experi-
ments’ suffice to attribute this level. The result is that,
without clear notif ication to the readership, poorly-
evidenced statements or ‘parachute type’ guidelines (i.e.
guidelines which seem obvious but have not been or can-
not be evidenced, like the recommendation of using a para-
chute when jumping out of a flying plane) are classified as
well evidenced. However, the real evidence level of these
IDSA guidelines is not high, which unfortunately is also
true for most nephrological recommendations [2].
For the sake of clarity, the present position statement
contains recommendations which are not based on a sys-
tematic literature review and are not supported by an evi-
dence review team. The reader should consider them rather
© The Author 2010. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For permissions, please e-mail: journals.permissions@oxfordjournals.org
 at Biom
edical Library G
ent on June 11, 2010 
http://ndtplus.oxfordjournals.org
D
ow
nloaded from
 
as practical expert advice than as real ‘guidelines’ which
are supposed to be supported by strong evidence.
IDSA only covered diagnosis and treatment, not preven-
tion. In this ERBPmonography,wewill startwith general as-
pects and prevention (‘General: tunnelled vs non-tunnelled
catheters’ and ‘Prevention of infection’ sections—two as-
pects not covered by the IDSA), only then followed by
comments and amendments of the IDSA guidelines per
se in ‘Overall aspects’ and ‘Unique aspects’ sections.
General: tunnelled vs non-tunnelled catheters
Permanent tunnelled central vein catheters are generally
considered as an ultimate resource for vascular access in
maintenance haemodialysis patients. One of the major ar-
guments for discouraging the use of tunnelled as well as
non-tunnelled catheters as an access for haemodialysis is
the risk of infection, which is a source of morbidity and
mortality, by inducing septic complications, metastatic in-
fectious disease, central vein thrombosis, malnutrition, in-
flammation and cardio-vascular damage.
Apart from their almost inevitable use in acute kidney
injury requiring renal replacement therapy, non-tunnelled
temporary catheters should be avoided as much as possi-
ble, since the risk of infection as compared to tunnelled
catheters is even higher, reflecting the lack of a cuff to
act as a barrier against inoculation from the exit site into
the systemic circulation.
Although the use of permanent catheters in chronic dial-
ysis is also generally discouraged as well [7], the proportion
of patients treated with them is still growing [10], and they
are a life-saving option in a substantial proportion of the
currently dialysed population who have run out of native
vascular access possibilities. Presumed reasons for their
high prevalence, especially in the Western World, are the
increased frequency of dialysis patients of older age, with
cardio-vascular disease and/or with diabetes mellitus, in
whom creation or repair of an autogenous fistula or graft
appears technically challenging, risky or impossible.
ERBP recommendations:
• A.1.1: The use of non-tunnelled catheters, except in
acute kidney injury (AKI), is undesirable. In chronic
maintenance haemodialysis patients, it is recommended
to remove temporary catheters as soon as possible, even
without or with only minor complications, and to have
them replaced preferentially by an arterio-venous fistula
(AVF) or, if that is impossible, an arterio-venous graft
(AVG) or, if that is impossible, a tunnelled central vein
catheter (CVC).
• A.2.2: If haemodialysis catheters are required either due
to need or because patients refuse an AVF, the occur-
rence of a catheter-related complication should be a
trigger to re-evaluate options for alternative access, such
as an AVF.
Prevention of infection
The IDSA guidelines do not consider recommendations on
preventive measures. ERBP recommends the following.
Catheter insertion and position
Catheter insertion should be performed under strict aseptic
circumstances and according to the conditions formulated
by European Best Practice Guidelines [7].
Table 1. IDSA guidelines of relevance to nephrology which are not discussed in the present position statement
Overall aspects
Diagnosis: intravenous catheter cultures
Culturing of the tip is preferred to that of the subcutaneous segment (3)
Swab drainage should be performed in case of exit exudate (6)
Diagnosis: blood cultures
Samples for culturing should be obtained before antibiotic treatment and be collected in the same volumes if taken from different sites (11)(20)
Appropriate preparation with antiseptics of both skin and catheter hub is necessary (13)(14)
General management of catheter-related infections
Empirical combination coverage is necessary for multiresistant gram negatives (e.g. Pseudomonas aeruginosa) in severely ill patients
(e.g. neutropenicsa) (26)
Empirical coverage is needed for candidaemia in patients at risk (e.g. during or after prolonged use of broad spectrum antibiotics) (28) b
Unique aspects
Treating patients receiving haemodialysis
Antibiotics can be discontinued if all blood cultures are negative (55)
Suppurative thrombophlebitis
The diagnosis of suppurative thrombophlebitis requires the presence of a positive blood culture plus the demonstration of a thrombus in the affected
vein by imaging (107)
Antimicrobial therapy for suppurative thrombophlebitis should last at least 3 to 4 weeks (110)
Persistent bloodstream infection and endocarditis
Trans-oesophageal endoscopic echocardiography (TEE) should be performed in case of CRBSI in association with prosthetic heart valve, pacemaker,
implantable defibrillator, persistent bacteraemia or fungaemia or persistent fever >72 h after start of appropriate treatment and catheter removal and
in any case of S. aureus CRBSI where duration of therapy less than 4 weeks is considered (112)
Unless dictated otherwise by clinical condition, TEE should be performed at the earliest 5–7 days after onset of bacteraemia or fungaemia to avoid
false negative results. In case of negative results, a repeat examination should be considered when endocarditis is suspected (113)
aExamples given in this table and text are not exhaustive. We refer the reader to the original text [1] for the full list of examples.
bFor details on how this should be done, please read in the text under ‘Antibiotic and antimycotic treatment’.
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Next to thrombosis, catheters inserted in the femoral po-
sition are also prone to a higher risk of infection and bac-
teraemia [11,12] than those in the internal jugular one and
should therefore be avoided as much as possible. If the
femoral site is nevertheless considered, the benefit of pre-
serving other central veins should be balanced with this
increased risk of infection. Of the remaining positions,
the subclavian is discouraged for other reasons than infec-
tious risk (stenotic complications). Among the internal
jugular positions, the right one is the most convenient [7].
ERBP recommendations:
• B.1.1 Catheters should be inserted under strict aseptic
conditions.
• B.1.2 The right internal jugular vein position is the
preferred location for insertion, followed by the left in-
ternal jugular vein position. The use of the femoral vein
position is discouraged.
• B.1.3 The use of the subclavian vein position is dis-
couraged for reasons not related to infection (frequent
stenosis).
Nursing care
Universal precautions using sterile material should be ap-
plied by caregivers whenever a central vein catheter is ma-
nipulated, connected or disconnected. The use of
disposable sterile material such as masks and gowns has
been suggested to protect against transmission of Staphylo-
cocci or other organisms [13,14], but, to the best of our
knowledge, their protective effect has not convincingly been
proven. In a collaborative intensive care unit (ICU) study, a
set of five different preventive interventions including full
barrier precautions was successfully implemented, but the
study did not evaluate the relative importance of each of
the individual interventions separately [15]. In another
study, the use of surgical face masks reduced bacterial con-
tamination of the area in front of the operator’s face [16],
who, however, was asked to talk during the 20-min observa-
tion period and to turn his/her head 90° every 30 s [16]. The
use of precautions such as masks and gowns should not be
considered as an excuse to relax on general hygienic and
sterile conditions.
Branching of central vein catheters to the dialysis ma-
chines as well as their disconnection is resource intensive,
and therefore sometimes two trained staff members (one
nurse focusing on the catheter and one helper for the man-
agement of the dialysis machine and to assist the nurse) are
deployed to enable connection and disconnection. The basic
and meticulous approach to handling catheters in a reliable
and sterile fashion at the time of both connection and dis-
connection or at any other time the catheter connection site
is manipulated forms the core of the prevention of infection.
ERBP recommendation:
• B.2.1 Universal precautions, a sterile environment and
aseptic technique should be applied at any occasion
when a venous catheter is manipulated, connected or dis-
connected.
Preventive antimicrobial catheter locks and catheter
surface treatment
There is increasing evidence that antimicrobial locks ap-
plied within the catheter lumen are effective at preventing
catheter-related bloodstream infections (CRBSI).
Some locks may have extra antimicrobial or biofilm-
removing properties [e.g. citrate, alcohol, ethylene diamine
triacetic acid (EDTA)]. On the contrary, heparin tends to
antagonize the bactericidal properties of certain antibiotics,
e.g. the aminoglycosides [17,18]. It also promotes biofilm
formation unless at very low concentrations [19].
The clinical advantages offered by citrate have been
confirmed in at least two meta-analyses [20,21]. Over
time, progressively lower concentrations of citrate have
been applied (from 46.7 to 4%) with even in the latter case
still significantly better results than with heparin [22–26].
In two studies, no benefit regarding infectious complica-
tions was observed for citrate at 4% [27,28].
Addition of antibiotics, either to heparin or to citrate so-
lutions, has an additional beneficial effect vs vehicle alone
[20].
One potential drawback of catheter locks is that some of
the contents spill over to the circulation at injection and in
between dialysis sessions [29,30]. A Food and Drug warn-
ing against citrate locks was issued in 2000 following a
fatal accident with the 46.7% solution [31]. The reported
fatal case was very likely related to abrupt hypocalcaemia
followed by cardiac arrest, due to intracardiac injection of
an excessive amount of 46.7% citrate, which is a potent
chelator of calcium. The 46.7 and 30% concentration
ranges have been considered unsafe [29]. For that reason,
the low 4% concentration might be preferred, as also pro-
posed by the American Society of Diagnostic and Inter-
ventional Nephrology (ASDIN) [32].
Of note, the capacity of citrate locks to prevent throm-
bus formation may be incomplete, especially at the highest
concentrations. Recently, several cases of symptomatic
pulmonary and cerebral embolisms were observed with
hypertonic citrate locks [33]. This is probably attributable
to seepage out of the lumen through the catheter side
holes, a process that might be exacerbated if the solution
is hyperosmolar.
For antibiotic locks, spillover may be a source of resis-
tance [34]. This issue has not been sufficiently studied and
remains a point of concern. With potentially toxic antibi-
otic locks such as those containing aminoglycosides,
trough levels should regularly be checked.
According to ERBP, there is not enough evidence of
clinical benefit of ethanol locks [35,36], although in vitro
data, both for ethanol alone at 60% and for an ethanol
30%/citrate 4% mixture, are promising [37,38]. Also, eth-
ylene EDTA has been proposed as an option [19,39].
For each type of lock, the corrosive or damaging poten-
tial on catheter polymers should be taken into consider-
ation, and the manufacturer of the catheter should provide
information regarding this issue.
Although findings might be influenced by differences in
the definition of CRBSI, it nevertheless is of interest to note
that several studies with application of locks achieve results
in the treatment armwhich are comparable to those obtained
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in centres of excellence with dedicated care to catheters
without applying locks [21]. Hence, the use of antimicrobial
locks should not be used as an excuse to relax on the appli-
cation of universal precautions and hygienic measures.
Several options of catheter surface modifications have
been proposed to combat biofilm, fibrin sheath, thrombus
or infection [40]. They essentially consist of silver sulfadia-
zine, heparin, TrilliumR [40] and/or coating with protective
polymer layers preventing BaSO4 release from the catheter
surface [41]. Results regarding clinical impact on coloniza-
tion are contradictory [42,43]. By lack of convincing clinical
data, it is at present difficult to justify their additional cost.
ERBP recommendations:
• B.3.1 The preventive use of antimicrobial locks is advo-
cated to reduce the rate of CRBSI.
• B.3.2 In view of the potential risks of spillover of the
locking solution, associated risks (arrhythmias, toxicity,
allergic reactions, development of resistance to antibio-
tics) should be balanced with the benefits in terms of
prevention of infection. Citrate locks have, for the time
being, most extensively been studied. The 4% solution
seems to offer at present the best benefit/risk ratio.
• B.3.3 Antimicrobial lock solutions should not replace hy-
gienic standardswith regard to catheter care and handling.
Exit-site dressings
Next to skin antisepsis before placement, sterile precautions
during placement and catheter site care at each dialysis ses-
sion, the site should be coveredwith a dressing as long as the
catheter is in place [44]. One meta-analysis comparing the
complication profile of transparent and gauze dressings
suggested a higher risk for catheter sepsis and bacteraemia
with transparent dressings [45]; another more recent meta-
analysis showed no differences but registered a high level of
uncertainty regarding the reliability of the studies included
[46]. With long-term catheters, gauze is the preferred
choice. Gauze should be replaced if it is no longer dry or
clean. The patient should be instructed to respect strict hy-
gienic measures, preserving the integrity and dryness of the
dressing, and should know what to do in case of disintegra-
tion or wetness.
ERBP recommendations:
• B.4.1 The catheter exit site should be covered by a dress-
ing as long as the catheter remains in place. The exit site
should be inspected at every haemodialysis session, and
the exit-site dressing should be replaced on a routine ba-
sis if it is no longer clean or intact.
• B.4.2 The patient should be instructed to maintain the
hygiene and integrity of the dressing.
Exit site and nasal antibiotic ointments
The use of antibiotic ointment at the insertion site has a ben-
eficial effect on CRBSIs and exit-site infections [47–49].
Their application is especially recommended after catheter
placement until the insertion site has healed [44]. Applica-
tion of mupirocin might be complicated by development of
resistance [50–52]. Prolonging antibiotic ointment applica-
tion after site healing probably offers no advantage and has
the potential to increase the risk for development of resis-
tance [48] and for Candida colonization [53].
In peritoneal dialysis (PD), ointments containing gen-
tamicin applied to the exit site have been shown to be
effective [54,55]. Gentamicin ointment was superior to
mupirocin in at least one study [55]. To the best of our
knowledge, similar treatment protocols have not been
studied with haemodialysis catheters. One study showed
that honey (Medihoney) was equivalent to mupirocin in
haemodialysis catheters [56]. One potential advantage
of Medihoney is that the theoretical risk of resistance is
lower than with mupirocin [56].
Another option is Polysporin triple ointment, containing
Bacitracin, gramicidin and polymyxin B, which was
shown to be superior to placebo in haemodialysis catheters
when applied to the exit site [57]. Comparative data with
mupirocin or other antibiotic ointment formulations are,
however, lacking.
Topical application of antibiotic ointments at the exit
site is also the first option in case of exit-site infection
without fever (see below, ‘Catheter removal and preserva-
tion of existing and future access options’ section).
Although there is ample literature on nasal mupirocin
ointment in peritoneal dialysis, information in haemodialy-
sis is scanty. In PD, nasal mupirocin decreases exit-site and
tunnel infection but not peritonitis [58,59]. Application is,
however, also related to an increase in MIC90 and frequent
recolonization [60]. According to ERBP, there is not enough
evidence to propagate nasal antibiotic ointment in a haemo-
dialysis setting.
ERBP recommendations:
• B.5.1 Application of antibiotic ointment at the exit site
should be considered after catheter placement until the
insertion site has healed but should be discontinued after
healing.
• B.5.2 With long-term exit-site and nasal antibiotic oint-
ment applications, especially of mupirocin, development
of resistance should be taken into account as an effect
counterbalancing the potential benefit on infectious
complications.
Overall aspects
Diagnosis: cultures of intravenous catheter
Several IDSA guidelines refer to the approach by the bacte-
riological laboratory; it might be important for the nephrol-
ogist to check the approach used in the laboratory to which
he/she usually sends samples. Qualitative broth cultures of
catheter tips are discouraged [61] (2), whereas the roll plate
technique of 5 cm of the catheter tip is recommended espe-
cially for short-term catheters (in place since less than
14 days) (7) and the quantitative broth culture (luminal
flushing or sonication) for catheters which have remained
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in place for a longer time. Other studies, however, showed
no differences between both approaches [62]. In general,
only detection of >15 colony forming units (CFU) is rele-
vant for roll plate and >102 for quantitative broth culture
(5)(90).
Although the IDSA guidelines explicitly recommend
culturing of catheter tips upon removal (1), questions can
be raised about the relevance of this approach. In a recent
study [63] on 312 patients with a positive catheter culture
and a negative blood culture, only eight patients (2.6%)
subsequently developed CRBSI with the same germ as
the one cultured from the tip, suggesting a low yield for
this costly and time-consuming strategy.
ERBP recommendations:
• C.1.1 Preferred laboratory approaches for cultures of ca-
theters are the semi-quantitative roll plate technique of
5 cm of the catheter tip (positive if >15 CFU are detected)
or the quantitative broth culture (luminal flushing or son-
ication, positive if >102 CFU are detected).
• C.1.2 In general, the therapeutic relevance of culturing
catheter tips in symptomatic patients with presumed
CRBSI should be considered low when blood cultures
are collected appropriately (see below, ‘Diagnostic blood
cultures’) and if appropriate antibiotic treatment is insti-
tuted (see below, ‘Antibiotic and antimycotic treatment’).
• C.1.3 Nephrologists should be aware whether the bacte-
riological laboratory analysing their samples applies the
appropriate techniques for culturing.
Diagnosis: blood cultures
A diagnostic test proposed in the IDSAmonography not ne-
cessitating catheter withdrawal is simultaneous sampling
from peripheral vein and from the catheter or from two dif-
ferent catheter lumens with appropriately marked bottles
[64] (15), with colony count from inside the catheter or
one of the two lumens being at least three times higher than
for the other sample. Alternatively, cultures from the periph-
eral blood sample should become positive at least 2 h later
than the ones from the catheter (differential time to positiv-
ity—DTP). Usefulness of DTP criteria in samples from two
catheter lumens has not been clarified [65–67] (17)(18)(19).
The ERBP considers that, although such recommenda-
tions may be valid for non-dialysis catheters, it may be
more difficult to implement these in haemodialysis. Firstly,
in many cases, it may be impossible to puncture a periph-
eral vein because of unavailability or because it is deemed
desirable to preserve veins for future access creation. Sec-
ondly, since many of the fever episodes necessitating blood
culture sampling occur during dialysis, during which high
blood flows are created through the catheter, it is likely that
blood cultures collected at that moment through the hae-
modialysis circuit, which is then directly linked to the cath-
eter, will offer similar results as peripheral blood, so that
peripheral sampling becomes redundant [68].
Fibrin sheath or biofilm collection via endoluminal
brushing has been proposed as another option [69,70]
but has been criticized because of risk of arrhythmia, em-
bolization and bacteraemia [71]. Hence, data at present are
not convincing enough to propagate its use.
When the approach of intradialytic collection through
the catheter is followed, a risk exists that some of the pos-
itive blood cultures relate to other infectious sources than
the catheter. To minimize this bias, alternative sources
should be excluded as much as possible by history taking,
clinical examination, imaging and targeted laboratory test-
ing (e.g. urine culture if possible).
ERBP recommendations:
• C.2.1 If a haemodialysis catheter is not removed, blood
cultures obtained during dialysis through the dialysis cir-
cuit linked to the catheter are a more realistic and
practical method to isolate an organism related to cath-
eter-associated infection than the dual-site approach
including also a peripheral vein sample, which is prop-
agated in the general population.
• C.2.2 When the catheter remains in place, alternative
sources of infection should be considered with an appro-
priate clinical history, examination, imaging and targeted
laboratory testing (e.g. urine culture if possible).
Diagnosis: registration
To guide empiric antibiotic therapy, it is of utmost impor-
tance that each haemodialysis centre maintains a database
of all suspected and proven CRBSI and episodes of bacter-
aemia in general, the causative organisms, their sensitivity
pattern to antibiotics, the potential source (catheter related,
pneumonia, urinary tract, etc.) and the outcomes after ther-
apeutic intervention. As a consequence, each unit should be
aware of the epidemiology of its catheter-related infections.
ERBP recommendation:
• C.3.1 Haemodialysis units should record all details re-
garding CRBSI epidemiology as well as about all
episodes of bacteraemia (events, causative organismswith
their susceptibility and evolution in response to therapy).
Unique aspects
Management of catheter infection in patients receiving
haemodialysis
Management of catheter infection is covered in two sec-
tions of the IDSA guidelines, one on general management
and one on management of haemodialysis catheters. As the
aim of this ERBP position statement is to discuss only hae-
modialysis catheter infections, we will merge the discus-
sion on these two topics under the present heading.
It should be noted that only catheter-related infection
and/or bacteraemia are discussed in this ERBP position
statement. Bacteraemia related to AVF or AVG or bacter-
aemia in the presence of a dialysis catheter but attributable
to other causes will not be covered.
Catheter removal and preservation of existing and future
access options. In the following clinical situations, the re-
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moval of the catheter should be considered as an additional
intervention to systemic antibiotic treatment (see below,
‘Antibiotic and antimycotic treatment’) (Figure 1): severe
complications (e.g. severe sepsis, suppurative thrombo-
phlebitis, metastatic infection); persistent bloodstream in-
fection or persistent clinical signs of infection in spite of
48–72h of appropriate antimicrobial therapy; infection with
Staphylococcus aureus, Pseudomonas aeruginosa, multire-
sistant organisms or fungi; and tunnel infection with fever.
For exit-site infection without fever, topical antibiotic ap-
Fig. 1. Flow chart summarizing a stepwise approach in case of suspected or proven catheter-related infection, including strategies for catheter removal
or preservation (salvage) of the catheter.
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plication might be attempted first (see above, ‘Exit site and
nasal antibiotic ointments’), but if infection does not re-
solve, systemic antibiotic treatment should be installed
(47). If systemic antibiotics also fail, the catheter should
be removed (49).
ERBP recommends the insertion of a new tunnelled cath-
eter preferably only when the patient remains afebrile for
48–72 h and shows a normalization of C-reactive protein
(CRP) and negative blood cultures. If the interval needs to
be prolonged for more than 48–72 h, a haemodialysis cath-
eter could be inserted in the intermediate at another site. A
strategy of placement per single dialysis session and remov-
al immediately afterwards might be considered as an alter-
native to minimize the risk of colonization.
However, in patients on haemodialysis, options for ac-
cess may be limited. Firstly, removal of a catheter will re-
quire another catheter to be inserted, increasing the
potential risk to generate further damage to the central
vein. This could have adverse consequences on the crea-
tion of an AVF in the future. Secondly, access options
may already be extremely limited and further attempts at
central vein cannulation impossible or risky. Of note, even
in the non-dialysed population, catheter-sparing strategies
have recently been employed to avoid unnecessary and
wasteful removal of catheters [71]. Therefore, removal of
the catheter might be considered, if clinically indicated, but
the strategy for future access should be part of this consid-
eration. For example, one should be sure that an alternative
site for insertion of a new catheter is available before the
original catheter is removed.
If any problems are anticipated, an alternative strategy is
to exchange the catheter over a guidewire. The optimal
time for guidewire-assisted replacement is after 48–72 h
of appropriate and effective antibiotic treatment (59). How-
ever, guidewire-assisted replacement increases the risk of
venous wall sclerosis and stenosis and is associated with
a high treatment failure rate. An alternative option is to
leave the catheter in place and to attempt catheter salvage
instilling an antibiotic lock (see below, ‘Antibiotic locks’)
in addition to systemic antibiotic therapy [72,73] (30)(60).
In a recent study, catheter salvage after incident bacterae-
mia achieved a cure, defined as no recurrence or compli-
cation, in 66.1% of cases [74]. Recurrent bacteraemia was
less common after catheter removal and reinsertion than
after salvage (8.1 vs 33.0%) but at the expense of dramat-
ically more complications (14.3 vs 0.9%). In this study,
salvage consisted of systemic antibiotic treatment but not
of antimicrobial or antibiotic locks. Both in the case of
guidewire-assisted replacement and of catheter salvage,
close follow-up by assessment of clinical status and repet-
itive blood cultures is imperative, and if persistent clinical
signs of infection and bacteraemia are found after 48–72 h,
the catheter should still be removed and replaced (33).
Surveillance blood cultures should be obtained 1 week
after completion of antibiotic treatment for CRBSI if the
catheter has not been removed. If these cultures are posi-
tive, the catheter should still be removed (67).
In order to preserve future access options, the practice of
peripheral blood culture sampling from vessels that poten-
tially could be used in the future for creation of vascular
access should be limited or avoided [7] (53).
Antibiotic and antimycotic treatment (Figure 2). In all
circumstances, systemic antibiotic therapy should be
administered.
For the approach in the general population, instructions
in the IDSA Guidelines are given separately for gram-
positive and gram-negative bacteria. According to ERBP,
empiric coverage should be inspired by the recorded in-
fections in the unit (see above, ‘Diagnosis: registration’).
If the registry indicates that current catheter infections are
regularly caused by both gram positives and gram nega-
tives, coverage for both classes of organisms should be
provided when empiric antibiotic therapy is started for
CRBSI, with eventual refinement of the antibiotic regime
once the responsible organism has been isolated and sen-
sitivities are known.
Although the choice of antibiotic treatment may depend
on individual preference, local or regional patterns, and/or
recommendations from hospitals and organizations, ac-
cording to ERBP, preference should be given to antibiotics
with a pharmacokinetic profile allowing administration af-
ter each dialysis session only; this is the case for vancomy-
cin, teicoplanin, cefazolin, ceftazidime and daptomycin.
Although the same is correct for aminoglycosides, it might
be impossible to reach appropriate trough levels as pursued
in the general population with simple post-dialysis admin-
istration, hence increasing the risk for ototoxicity, loss of
residual renal function, treatment failure and development
of resistance. Nevertheless, in view of their rapid bacteri-
cidal effect, a single shot of aminoglycosides might be
considered useful. If no alternative is available, a longer
therapeutic course might be considered; in that case, ad-
ministration 1 h before dialysis followed by a highly effi-
cient dialysis procedure is probably the most efficient
approach to mimic pharmacokinetics and pharmacody-
namics observed in the general population.
In settings where methicillin-resistant S. aureus (MRSA)
is highly prevalent, vancomycin or teicoplanin is the first
choice for empirical treatment of gram-positive germs (23).
In patients on empirical vancomycin or teicoplanin in
whom infection with methicillin-sensitive S. aureus ap-
pears, antibiotic treatment should be switched to cefazolin
(62). Potential advantages of cefazolin are its broader spec-
trum; its favourable pharmacokinetics necessitating only
IV administration in direct relation to dialysis compared
to a need for additional interdialytic IV or PO administra-
tions for the methicillin group; and compared to vancomy-
cin, a bactericidal instead of a bacteriostatic activity.
Continued treatment with vancomycin in case of methicil-
lin sensitivity substantially increases the risk of treatment
failure [75].
When minimum inhibitory concentration (MIC) for van-
comycin exceeds 2 µg/mL, alternative antibiotics should be
used such as daptomycin [76] (23). Daptomycin has also
the advantage of being cleared by the kidneys, which al-
lows long intervals between administrations. In haemodia-
lysis patients, post-dialysis administration of one dose (4 to
6 mg/kg depending on the seriousness of the infection) is
considered sufficient. Daptomycin is, however, not yet
available in all European countries (e.g. not in Belgium).
Linezolid should not be used for empirical treatment (24).
For candidaemia, echinocandin should preferably be used,
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with fluconazole only for selected cases (e.g. if risk of Can-
dida krusei or Candida glabrata is low) [77] (29). Candida
infection is, however, rare in haemodialysis catheters, prob-
ably reflecting a different immune predisposition as com-
pared to other populations at risk (e.g. HIV, long-term
antibiotic treatment). Candida catheter infection is associat-
ed with a high rate of treatment failure or early recurrence,
so that catheter removal is a first-line therapeutic option.
Usual length of treatment for uncomplicated cases is
3 weeks. For tunnel infection without bacteraemia or fun-
gaemia and if the catheter has been removed, 7 to 10 days
is sufficient. Prolonged (6 weeks) antibiotic treatment
should be administered if fungaemia or bacteraemia per-
sists 48–72 h after catheter removal, since very likely seri-
ous metastatic complications such as endocarditis are
present; 6-week treatment should be installed as well in
case of a definite diagnosis of metastatic infection (31).
For osteomyelitis, antibiotic treatment should be prolonged
to 8 weeks.
For uncomplicated infections with other organisms than
those mentioned above, antibiotic treatment without cath-
eter removal should be attempted first (both systemic and
lock), because catheter reinsertion is not free of risk (35).
With a single positive blood culture of coagulase-negative
Staphylococci, a careful clinical evaluation and additional
positive cultures should have been obtained before therapy
and/or catheter removal [78] (38).
For antibiotics with substantial removal via the kidneys,
such as vancomycin, residual renal function should be tak-
en into account when determining the dose and frequency
of administration. Highly efficient dialysis strategies (high-
flux haemodialysis, haemodiafiltration, daily dialysis, pro-
longed dialysis sessions such as in nocturnal dialysis) can
equally remove substantial amounts of antibiotic [79], and
also in these cases the dose should be adapted accordingly.
To guide treatment, pre-dialysis trough levels are the opti-
mal approach.
ERBP recommendations:
• D.1.1 Systemic antibiotic treatment should be always ad-
ministered as part of the therapy of catheter infection.
• D.1.2 Catheter removal is the first therapeutic option in
case of severe complications and metastatic infections;
infection with S. aureus, P. aeruginosa, multiresistant
organisms or fungi; and tunnel infection with fever.
• D.1.3 The therapeutic advantages of catheter removal
should be balanced against the risk of reinsertion, and
removal might not be appropriate, if an alternative inser-
tion site is not available or if reinsertion of a catheter is
associated with excess risk. In this scenario, the catheter
could be replaced over a guidewire, preferably 3 days
after appropriate and effective antibiotic treatment.
• D.1.4 If guidewire-assisted exchange is also impossible
or too risky, a valid option is to keep the catheter in situ
and to combine this with a treatment consisting of sys-
temic antibiotics and antibiotic locks (catheter salvage).
• D.1.5 With either guidewire-assisted exchange or if the
original catheter is left in place for salvage and if the
clinical picture is not improving or if blood cultures re-
main positive after 48–72 h, the option to remove the
catheter should be re-evaluated as indicated under D.1.2.
• D.1.6 If a catheter is not removed, blood cultures should
be checked 1 week after completion of antibiotic treat-
ment, and if those cultures remain positive, the catheter
should be removed.
• D.1.7 For exit-site infection without fever, topical antibi-
otic application can be considered as an alternative. If
infection does not resolve, systemic antibiotics should
be administered. For tunnel infection without fever, sys-
temic antibiotics are the preferred option, although
peroral treatment may be sufficient. If these treatments
fail, the catheter should be removed.
• D.1.8 When haemodialysis catheter infection is sus-
pected, primary antibiotic approach should be inspired
by the previously recorded responsible organisms in the
unit. If both gram-positive and gram-negative organisms
are registered on a regular basis, both types should be
covered with eventual refining of the antibiotic regime
once the organisms and their sensitivities are known.
• D.1.9 In general, antibiotics necessitating administration
post-dialysis only (vancomycin, teicoplanin, cefazolin,
ceftazidime, daptomycin) should be preferred.
• D.1.10 Vancomycin or teicoplanin is the first choice for
empirical therapy of gram positives in settings where
MRSA is highly prevalent.
• D.1.11 For methicillin-sensitive S. aureus, haemodialy-
sis patients should receive cefazolin.
• D.1.12 Doses of antibiotics of which the active concentra-
tion is affected by residual renal function and/or dialysis
adequacy should be adapted accordingly. If possible, pre-
dialysis trough levels should be obtained to guide therapy.
Antibiotic locks
Recommendations for removal (either with catheter-free
interval or over a guidewire) should be applied as detailed
above (‘Catheter removal and preservation of existing and
future access options’). If removal is deemed unnecessary,
undesirable or impossible, antibiotic lock is an important
therapeutic option (71). Antibiotic lock should not be
used alone but always in conjunction with systemic anti-
biotics for the recommended periods (see above, ‘Antibi-
otic and antimycotic treatment’) (69). Although dwell
times generally should not exceed 48h and even 24 h
for ambulatory patients with femoral catheters, for haemo-
dialysis lock renewal after every dialysis session is consid-
ered sufficient (70). For vancomycin, the concentration in
the lock should at least be 1000 times higher than the
MIC of the micro-organism involved [80] (73). For all
other antibiotics, at least 100-fold greater than therapeutic
plasma concentrations should be pursued [68]. Antibiotic
concentrations as they are reported in the literature are
summarized in Table 2.
The success rate of salvage in case of S. aureus is low
(approximately 40%) [81] and therefore should be consid-
ered only in problematic cases. Success rate for Enterococ-
cus is approximately 60% [82]. For all other organisms,
success rates are substantially higher [68].
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Antibiotic locks can be dissolved in different vehicles.
Some of these might have extra antimicrobial or biofilm
removing properties (see above, ‘Preventive antimicrobial
catheter locks and catheter surface treatment’). Urokinase
and other thrombolytic locks are not recommended as ad-
junctive therapy for patients with CRBSI (37).
ERBP recommendations:
• D.2.1 When catheter salvage is attempted, the combina-
tion of an antibiotic lock and systemic antibiotic therapy
should be applied.
• D.2.2 Salvage of the catheter in case of S. aureus infec-
tion should only be considered when catheter removal
and replacement are expected to be problematic.
• D.2.3 Urokinase and other thrombolytic locks are not re-
commended. The use of heparin locks alone in case of
CRBSI is discouraged.
Diagnosis and management of an outbreak of CRBSI
Criteria defining the exposed patients should be estab-
lished (117). A root cause analysis or case control study
should be undertaken to elucidate the potential aetiology
of contamination (118). Micro-organism patterns should
be evaluated by studying antibiotic sensibility and molec-
ular fingerprinting to understand recurrence and relapsing
episodes (119).
ERBP recommendation:
• D.3.1 Outbreaks of CRBSI should be scrupulously
checked by case definition, case control studies and root
cause analysis.
Standard care
Centres should establish standard care protocols around
prevention and treatment and a quality improvement pro-
gram. In case of an outbreak of CRBSI, the root cause
analysis should assess compliance with these protocols.
If compliance is below expectation, retraining and eventu-
ally reorganization of care should be considered. If compli-
ance with the protocol is deemed appropriate, modification
of the protocol could be considered and the process of care
re-audited.
ERBP recommendation:
• D.4.1 Standard protocols detailing all aspects of preven-
tive care (catheter manipulation and exit-site care),
diagnosis, treatment and follow-up should be established
in each centre. These protocols should include hygienic
measures for catheter manipulation (see above, ‘Nursing
care’ and ‘Exit-site dressings’) and should be assessed by
quality control and quality improvement strategies, in
conjunction with clinical audit. In case of an outbreak, ad-
herence to those protocols should be improved if it is
considered inappropriate. If adherence is appropriate,
modification of the protocols should be considered in
function of the findings.
Research recommendations
Studies of outcome (or surrogate endpoints like CRP)
with central vein catheters for haemodialysis compared
to other access methods, if optimum prevention against
CRBSI is applied
International multicentric registry of frequency of access
infection, type of organism, resistance profile, recur-
rence profile
Evaluation whether wearing a mask (doctor, nurse, pa-
tient) during catheter insertion/manipulation protects
against catheter infection
In vivo studies comparing citrate with alternative lock
vehicle solutions such as EDTA, ethanol, urokinase
Head-to-head comparisons of lock solutions with differ-
ent citrate concentrations
Studies on the effect of spillover of antibiotics from pre-
ventive antibiotic locks on antibiotic resistance and on the
impact of citrate spillover on symptoms and side effects
Studies on the impact of lock solutions on catheter
polymers
Comparison of topical applications of gentamicin, Med-
ihoney or Polysporin Triple ointments in the prevention
of infection, as compared to mupirocin ointment
Studies on application of hypertonic saline solutions at
exit site as preventive measure
To evaluate the laboratory strategies for culturing dialy-
sis catheters in Europe
To check the concordance between blood cultures
taken from the dialyser blood lines and peripheral blood
samples
Studies of protocols optimizing aminoglycoside phar-
macokinetics in haemodialysed patients
Studies comparing the impact on catheter infection of
broad catheter salvage (including systemic antibiotics
as well as antibiotic and antimicrobial locks) vs removal
and reinsertion
Studies on the usefulness of antibiotic locks in infec-
tions with other organisms than S. aureus, P. aeruginosa
when catheters are left in place
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Table 2. Antibiotic concentrations applied in locksa
Antibiotic Concentration (mg/mL)
Vancomycin 2.5–25
Gentamycin 4–40b
Tobramycin 5
Minocycline 3
Cefazolin 10
Ceftazidime 10
aMay be diluted 1/1 or 2/1 in another vehicle such as citrate or heparin
solution.
bThe preferred concentration is 4 mg/mL because of risk for ototoxicity
with spillover at higher concentrations; sources: Yahav et al. [20], Onder
et al. [73] and Allon [68].
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